sciencyelmira Profile Banner
Elmira Khabusheva Profile
Elmira Khabusheva

@sciencyelmira

Followers
752
Following
17K
Media
543
Statuses
8K

@Goodell_Lab postdoc working on #AML. ex short-term FIMM postdoc. Tweets are my own.

Houston, TX
Joined January 2011
Don't wanna be here? Send us removal request.
@sciencyelmira
Elmira Khabusheva
12 days
Thrilled to share that my third year as a postdoc in Peggy’s Lab @Goodell_Lab begins with a paper published in @CellCellPress. Forever grateful to @Gandhar_Datar @Goodell_Lab @SuperSciJew for brining me into this incredible collaborative multidisciplinary project.
@Gandhar_Datar
Gandhar Datar
12 days
(1/10) How do diverse leukemia mutations converge on the same molecular program? In our new study @CellCellPress,the @RibackLab and @Goodell_Lab show that disparate mutations rewire shared protein networks to form nuclear condensates called coordinating bodies (C-bodies).🫧
2
0
36
@NatureNano
Nature Nanotechnology
3 days
New paper: Nanoscale domains govern local diffusion and ageing within fused-in-sarcoma condensates Single-molecule tracking reveals nanoscale domains within #FUS #condensates that migrate to the condensate surface during aging, seeding ALS fibrils. https://t.co/pxvUdPGDC5
1
12
56
@ElizSMcKenna
Elizabeth McKenna
3 days
Exciting news that two menin inhibitors (revumenib and ziftomenib) are now approved for NPM1-mutant AML! Really cool to see the initial finding from @Armstrong_dfci's lab published in 2016 in @CD_AACR translated all the way to the clinic! https://t.co/fA5oaYpSbv
@AACR
AACR
3 days
The @US_FDA approved the menin inhibitor ziftomenib for certain adults with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation and without any alternative treatment options:
0
3
27
@TaylorJ_MD
Taylor Lab UM
3 days
Now we have a second menin inhibitor approved for R/R NPM1c AML! FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation #leusm #AMLsm #leukemia
Tweet card summary image
fda.gov
On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.).
0
1
9
@FDAOncology
FDA Oncology
3 days
#FDA approves a treatment for relapsed or refractory acute myeloid leukemia. https://t.co/igJHDdKMlb
1
6
16
@marinkazitnik
Marinka Zitnik
4 days
People say, “you become the average of your five closest friends.” But in tissues, a perturbed cell does NOT simply become the average of its nearest neighbors. Sometimes a cell breaks from the crowd. Sometimes signals travel far. Sometimes niches overpower proximity. That is
0
33
214
@LabWaggoner
Waggoner Lab
5 days
Integrated live-cell imaging of LPS-stimulated human blood monocytes revealed that a large % remained viable & contributed negligible IL-1β, while <10% underwent NLRP3 activation, GSDMD pyroptosis, & secreted IL-1β @NatImmunol 🇯🇵🇧🇪 https://t.co/B4777SSm98 Paradigm changing!!
0
4
21
@EpigenomeTech
Epigenome Technologies Inc.
5 days
Epigenetics Update – Reprogramming of H3K36me2 guides lineage-specific post-implantation de novo DNA methylation https://t.co/EFSM7LcbDB #Epigenetics #DNAm #H3K36me2 #Development --- High-resolution insights without cell sorting; https://t.co/WmSYDGXnzb
1
15
63
@sciencyelmira
Elmira Khabusheva
4 days
Seeing this for the third time but still amused how beautiful it is!
@EpigenomeTech
Epigenome Technologies Inc.
5 days
Epigenetics Update - CRISPR live-cell imaging reveals chromatin dynamics and enhancer interactions at multiple non-repetitive loci https://t.co/snmRdlQA5o #Epigenetics #CRISPR #Chromatin --- Empower your research with high-res epigenetic insights at https://t.co/WmSYDGWPJD
0
0
3
@EytanRuppin
Eytan Ruppin, MD, PhD
6 days
Huge congrats to Sanju, our co-authors, and our collaborators! Proud to share this work on identifying the mechanisms by which drugs kill cancer through systematic gene KO viability screenings!
@Sanjusinha7
Sanju Sinha
6 days
Most current drug discovery efforts is structure-based eg. create small molecules or antibodies that best binds X. However, a drug may not drive its efficacy from its strongest binder. Taking a step away from structure-paradigm, we reason that if a CRISPR knockout of a gene
1
9
43
@CarmeloGurnari
Carmelo Gurnari
4 years
Our contribution to the field of MDS! Multi-institutional efforts and great collaborations! @VisconteValeria @leukaemielabor @pagliuca_simona @yihong_guan @AwadaHassan_ @babal_jha @MDSFoundation @aamdsif @unitorvergata2 @BloodAdvances
5
16
60
@LukensJohnR
John Lukens
8 days
Loss of MeCP2 results in cGAS-STING-mediated inflammation. Points towards a potential role for cGAS-STING-driven inflammation in Rett syndrome. https://t.co/NY7eJmElAg
Tweet card summary image
nature.com
Nature Communications - Mecp2 deficiency underlies Rett syndrome, a genetic disorder presenting with chronic low-grade inflammation of unknown origin. Here, the authors show that Mecp2 is a central...
1
15
106
@kidney_boy
Joel M. Topf, MD FACP
10 days
@FreelyFiltered And his state of the art lecture #KidneyWk
1
4
6
@NatureBiotech
Nature Biotechnology
10 days
CRISPR live-cell imaging reveals chromatin dynamics and enhancer interactions at multiple non-repetitive loci https://t.co/5VtEnCmKEB
0
69
227
@sanjeevtmc
Sanjeev Shukla
12 days
Our new study reveals how hypoxia-induced CTCF drives PRMT5 upregulation to rewire TCF3 splicing, promoting breast cancer invasion and EMT. Congrats to @Mutnuru_SA for key insights into chromatin regulation, splicing & metastasis! Read here: https://t.co/OGCP4fi61e
7
13
64
@daria_rom__
Daria R
3 months
Congrats to everyone involved!
@BockLab
Christoph Bock Lab @ CeMM & MedUni Vienna
3 months
🛡️How do macrophages tailor their defenses to different pathogens? Our new paper in @CellSystems combines dense multi-omics time series with high‐content CRISPR screens (CROP-seq) to map the regulatory landscape underlying macrophage immune responses. #Immunity #Screening (1/9)
0
1
2
@BCMFromtheLabs
From the Labs at Baylor College of Medicine
12 days
1
8
25
@GitlinLab_MSK
Gitlin Lab MSK
13 days
🚨Thrilled to share our latest work, published online today @Nature in which we decipher mechanisms underlying the enigmatic VEXAS syndrome - a huge team effort @MSKCancerCenter led by superstars @VarunNarendraMD + @das_tandrila 🧵1/ https://t.co/0ubLHCbR9I
nature.com
Nature - Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome
10
37
142